A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

NCT06172322 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

HR Positive/HER-2 Negative Breast Cancer

Interventions

DRUG: NTQ1062 with Fulvestrant

Sponsor

Nanjing Chia-tai Tianqing Pharmaceutical